United Kingdom
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Ubiquigent.
Dundee, UK, and San Francisco, US, 15 October 2024: Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases. The partnership will combine Alleo’s AI-based approach to developing novel therapeutics with Ubiquigent’s platform and expertise in the field of DUB focused drug discovery. Financial details were not disclosed.
This is the News section of the company profile page for Ubiquigent on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
